


Amendments to the Claims

1. (Original) A phosphodiesterase 10A inhibitor containing as an active ingredient a pyrazolo[1,5-a]pyridine derivative represented by the following general formula (1):



wherein R¹ and R² are each independently a hydrogen atom or a lower alkyl group having 1 to 4 carbons; and R³ is a hydrogen atom, a lower alkyl group having 1 to 4 carbons, or a lower alkoxyl group having 1 to 3 carbons.

2. (Original) The phosphodiesterase 10A inhibitor according to claim 1, wherein the compound represented by the general formula (1) is 3-isobutyryl-2-isopropyl pyrazolo[1,5-a]pyridine.

3. (Currently amended) A therapeutic or prophylactic agent for Parkinson's disease containing as an active ingredient the phosphodiesterase 10A inhibitor according to claim 1-~~or~~2.

4. (Currently amended) A therapeutic or prophylactic agent for Huntington's disease containing as an active ingredient the phosphodiesterase 10A inhibitor according to claim 1-~~or~~2.

5. (Currently amended) A therapeutic or prophylactic agent for Alzheimer's disease containing as an active ingredient the phosphodiesterase 10A inhibitor according to claim 1-~~or~~2.

6. (Currently amended) A therapeutic or prophylactic agent for schizophrenia containing as an active ingredient the phosphodiesterase 10A inhibitor according to claim 1-~~or~~2.
7. (New) A therapeutic or prophylactic agent for Parkinson's disease containing as an active ingredient the phosphodiesterase 10A inhibitor according to claim 2.
8. (New) A therapeutic or prophylactic agent for Huntington's disease containing as an active ingredient the phosphodiesterase 10A inhibitor according to claim 2.
9. (New) A therapeutic or prophylactic agent for Alzheimer's disease containing as an active ingredient the phosphodiesterase 10A inhibitor according to claim 2.
10. (New) A therapeutic or prophylactic agent for schizophrenia containing as an active ingredient the phosphodiesterase 10A inhibitor according to claim 2.